Jack Anders - 17 Mar 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RVMD
Reported as of: 17 Mar 2023
Net transaction value: -$14,484
SEC form: 4
Accepted by SEC: 21 Mar 2023, 20:33:31 UTC
Prior SEC filing: 03 Mar 2023
Next SEC filing: 22 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 21 Mar 2023.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Mar 2023, 20:33.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: -$14,484.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $14,484
Shares: -665
Change %: -1.2%
Price: $21.78
Shares after: 55,233
Date: 17 Mar 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

Footnote F2

This transaction was executed in multiple trades in prices ranging from $21.4075 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 47,750 RSUs.